169 related articles for article (PubMed ID: 25113640)
1. Expression and localization of estrogen receptor in human breast cancer and its clinical significance.
Li L; Wang Q; Lv X; Sha L; Qin H; Wang L; Li L
Cell Biochem Biophys; 2015 Jan; 71(1):63-8. PubMed ID: 25113640
[TBL] [Abstract][Full Text] [Related]
2. The Relative Expression of ERα Isoforms ERα66 and ERα36 Controls the Cellular Response to 24R,25-Dihydroxyvitamin D3 in Breast Cancer.
Verma A; Cohen DJ; Jacobs TW; Boyan BD; Schwartz Z
Mol Cancer Res; 2021 Jan; 19(1):99-111. PubMed ID: 33082240
[TBL] [Abstract][Full Text] [Related]
3. ERα36-GPER1 Collaboration Inhibits TLR4/NFκB-Induced Pro-Inflammatory Activity in Breast Cancer Cells.
Notas G; Panagiotopoulos A; Vamvoukaki R; Kalyvianaki K; Kiagiadaki F; Deli A; Kampa M; Castanas E
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299224
[TBL] [Abstract][Full Text] [Related]
4. 14-3-3τ drives estrogen receptor loss via ERα36 induction and GATA3 inhibition in breast cancer.
Garan LAW; Xiao Y; Lin WC
Proc Natl Acad Sci U S A; 2022 Oct; 119(43):e2209211119. PubMed ID: 36252018
[TBL] [Abstract][Full Text] [Related]
5. Clinical and Biological Significance of
Nagel A; Szade J; Iliszko M; Elzanowska J; Welnicka-Jaskiewicz M; Skokowski J; Stasilojc G; Bigda J; Sadej R; Zaczek A; Markiewicz A
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 30995757
[TBL] [Abstract][Full Text] [Related]
6. Expression patterns of ERα66 and its novel variant isoform ERα36 in lactotroph pituitary adenomas and associations with clinicopathological characteristics.
Mahboobifard F; Bidari-Zerehpoosh F; Davoudi Z; Panahi M; Dargahi L; Pourgholami MH; Sharifi G; Izadi N; Jorjani M
Pituitary; 2020 Jun; 23(3):232-245. PubMed ID: 32026205
[TBL] [Abstract][Full Text] [Related]
7. From ERα66 to ERα36: a generic method for validating a prognosis marker of breast tumor progression.
Chamard-Jovenin C; Jung AC; Chesnel A; Abecassis J; Flament S; Ledrappier S; Macabre C; Boukhobza T; Dumond H
BMC Syst Biol; 2015 Jun; 9():28. PubMed ID: 26080803
[TBL] [Abstract][Full Text] [Related]
8. Significance of estrogen receptor subtypes in breast tumorigenesis and progression.
Sun W; Gu C; Xia M; Zhong G; Song H; Guo J
Tumour Biol; 2014 Sep; 35(9):9111-7. PubMed ID: 25027393
[TBL] [Abstract][Full Text] [Related]
9. Expression of HER2 and estrogen receptor alpha depends upon nuclear localization of Y-box binding protein-1 in human breast cancers.
Fujii T; Kawahara A; Basaki Y; Hattori S; Nakashima K; Nakano K; Shirouzu K; Kohno K; Yanagawa T; Yamana H; Nishio K; Ono M; Kuwano M; Kage M
Cancer Res; 2008 Mar; 68(5):1504-12. PubMed ID: 18316615
[TBL] [Abstract][Full Text] [Related]
10. The elevated level of ERα36 is correlated with nodal metastasis and poor prognosis in lung adenocarcinoma.
Zhang S; Qiu C; Wang L; Liu Q; Du J
Steroids; 2014 Sep; 87():39-45. PubMed ID: 24928730
[TBL] [Abstract][Full Text] [Related]
11. Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer.
Bostner J; Alayev A; Berman AY; Fornander T; Nordenskjöld B; Holz MK; Stål O
Breast Cancer Res Treat; 2018 Feb; 168(1):17-27. PubMed ID: 29128895
[TBL] [Abstract][Full Text] [Related]
12. ERα36, a variant of estrogen receptor α, is predominantly localized in mitochondria of human uterine smooth muscle and leiomyoma cells.
Yan Y; Yu L; Castro L; Dixon D
PLoS One; 2017; 12(10):e0186078. PubMed ID: 29020039
[TBL] [Abstract][Full Text] [Related]
13. Concomitant high expression of ERα36, EGFR and HER2 is associated with aggressive behaviors of papillary thyroid carcinomas.
Dai YJ; Qiu YB; Jiang R; Xu M; Zhao L; Chen GG; Liu ZM
Sci Rep; 2017 Sep; 7(1):12279. PubMed ID: 28947799
[TBL] [Abstract][Full Text] [Related]
14. Membrane estrogen signaling enhances tumorigenesis and metastatic potential of breast cancer cells via estrogen receptor-α36 (ERα36).
Chaudhri RA; Olivares-Navarrete R; Cuenca N; Hadadi A; Boyan BD; Schwartz Z
J Biol Chem; 2012 Mar; 287(10):7169-81. PubMed ID: 22247547
[TBL] [Abstract][Full Text] [Related]
15. Effect of 17β-estradiol on estrogen receptor negative breast cancer cells in an osteolytic mouse model.
Cohen DJ; Patel V; Verma A; Boyan BD; Schwartz Z
Steroids; 2019 Feb; 142():28-33. PubMed ID: 29133279
[TBL] [Abstract][Full Text] [Related]
16. Expression of estrogen receptor α variants and c-Fos in rat mammary gland and tumors.
Gutiérrez A; Sambuco L; Álvarez L; Núñez M; Bergoc R; Zotta E; Martín G; Randi A
J Steroid Biochem Mol Biol; 2020 May; 199():105594. PubMed ID: 31968225
[TBL] [Abstract][Full Text] [Related]
17. ERα36, a new variant of the ERα is expressed in triple negative breast carcinomas and has a specific transcriptomic signature in breast cancer cell lines.
Pelekanou V; Notas G; Kampa M; Tsentelierou E; Radojicic J; Leclercq G; Castanas E; Stathopoulos EN
Steroids; 2012 Aug; 77(10):928-34. PubMed ID: 22198466
[TBL] [Abstract][Full Text] [Related]
18. [Expression of estrogen receptor, progesterone receptor, and human epithelial growth factor receptor 2 in breast cancer and the significance thereof: analysis of 910 cases].
Liu RB; Zhou XH; Wang JN; Liang HZ; Li XX; Wu ZH; Ye JL; Wang SM
Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(48):3397-400. PubMed ID: 19159568
[TBL] [Abstract][Full Text] [Related]
19. Expression of ERα36 in gastric cancer samples and their matched normal tissues.
Wang J; Li J; Fang R; Xie S; Wang L; Xu C
Oncol Lett; 2012 Jan; 3(1):172-175. PubMed ID: 22740875
[TBL] [Abstract][Full Text] [Related]
20. Cytoplasmic localization of alteration/deficiency in activation 3 (ADA3) predicts poor clinical outcome in breast cancer patients.
Mirza S; Rakha EA; Alshareeda A; Mohibi S; Zhao X; Katafiasz BJ; Wang J; Gurumurthy CB; Bele A; Ellis IO; Green AR; Band H; Band V
Breast Cancer Res Treat; 2013 Feb; 137(3):721-31. PubMed ID: 23288344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
